Table 2.
Most Recent Antiretroviral Drug Regimens During Pregnancy by Study Arm
| Study Group | Maternal Antiretroviral Regimen | N (% Within Tenofovir Exposure Group) |
|---|---|---|
| Tenofovir exposed (n = 74)a | TDF-FTC-ATVr | 39 (53) |
| TDF-FTC-DRVr | 12 (16) | |
| TDF-FTC-RAL | 6 (8) | |
| TDF-FTC-LPVr | 4 (5) | |
| TDF-FTC-RAL-ATVr | 3 (4) | |
| TDF-FTC-RPV | 2 (3) | |
| TDF-FTC-ZDV-RPV | 2 (3) | |
| Otherb | 6 (8) | |
| Tenofovir unexposed (n = 69)c | ZDV-3TC-LPVr | 27 (39) |
| ABC-3TC-ZDV | 16 (23) | |
| ZDV-3TC-DRVr | 5 (7) | |
| ABC-3TC-ATVr | 3 (4) | |
| ZDV-3TC-NFV | 3 (4) | |
| ABC-3TC-DRVr | 2 (3) | |
| ZDV-3TC-RAL | 2 (3) | |
| Otherd | 11 (16) |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; DRV, darunavir; ETR, etravirine; FPV, fosamprenavir; FTC, emtricitabine; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NVP, nevirapine; r, ritonavir (boosting dose); RAL, raltegravir; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
a In the tenofovir-exposed group, 29 (39%) women were already receiving their TDF-containing antiretroviral regimen when they became pregnant, while 11 (15%), 30 (41%), and 4 (5%) started that regimen in the first, second, and third trimesters, respectively.
b Other regimens used by 1 (1%) woman in tenofovir-exposed group included: TDF-FTC-ABC-RAL, TDF-FTC-FPVr, TDF-FTC-NVP, TDF-FTC-SQVr, TDF-ZDV-ATVr, TDF-FTC-RAL-DRVr.
c In the tenofovir-unexposed group, 18 (26%) women were already receiving their antiretroviral regimen prior to pregnancy, while 17 (25%), 31 (45%), and 3 (4%) started their pregnancy regimen in the first, second, and third trimesters, respectively.
d Other regimens used by 1 (1%) woman in tenofovir-unexposed group included: ABC-3TC-ATV, ZDV-3TC-ATVr, ZDV-3TC-NVP, ZDV-3TC-MVC, ETR-RAL-DRVr, ABC-3TC-ZDV-NVP, ABC-3TC-ZDV-RAL, ZDV-3TC RAL-LPVr, ZDV-3TC-RAL-MVC-DRVr, ZDV-3TC-ETR-DRVr, 3TC-LPVr.